(L4K3) Lyxor MSCI China - Acc - Ratings and Ratios
China, Equity, ETF, Large-Cap, Mid-Cap
Description: L4K3 Lyxor MSCI China - Acc
The Lyxor MSCI China UCITS ETF - Acc (XETRA:L4K3) is an exchange-traded fund that tracks the Morningstar China TME NR USD index, providing investors with exposure to the Chinese equity market. As an ETF listed on XETRA, it is subject to German regulations and is accessible to a broad range of investors.
Analyzing the ETFs technical data, the current price of 17.49 is above its 20-day Simple Moving Average (SMA) of 16.76, indicating a short-term uptrend. However, it is below the 50-day SMA of 17.98, suggesting a potential resistance level. The 200-day SMA at 16.50 provides a longer-term bullish signal. The Average True Range (ATR) of 0.46, or 2.62% of the current price, indicates moderate volatility. Considering the 52-week high and low of 19.87 and 13.28, respectively, the ETF is currently 87.8% of the way between its 52-week low and high.
Fundamentally, the ETF has an Assets Under Management (AUM) of 266.97 million EUR, indicating a relatively modest size. This could impact liquidity, although being listed on XETRA helps mitigate this concern to some extent.
By combining technical and fundamental insights, a forecast can be derived. Given the ETFs current position relative to its SMAs and its ATR, a potential trading range could be between 16.50 (200-day SMA) and 19.87 (52-week high). A break above the 50-day SMA (17.98) could signal further upside, potentially towards the 52-week high. Conversely, a drop below the 200-day SMA could indicate a return towards the 52-week low. Therefore, a likely forecast is that the ETF will continue to trade within this range, with a potential bias towards the upside if it can sustainably break above 17.98.
Additional Sources for L4K3 ETF
L4K3 ETF Overview
Market Cap in USD | 314m |
Category | China Equity |
TER | 0.29% |
IPO / Inception | 2018-07-05 |
L4K3 ETF Ratings
Growth Rating | -14.1 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -4.21 |
Analysts | - |
Fair Price Momentum | 16.60 EUR |
Fair Price DCF | - |
L4K3 Dividends
Currently no dividends paidL4K3 Growth Ratios
Growth Correlation 3m | 44.2% |
Growth Correlation 12m | 70.8% |
Growth Correlation 5y | -63.9% |
CAGR 5y | -3.87% |
CAGR/Max DD 5y | -0.07 |
Sharpe Ratio 12m | 0.14 |
Alpha | 12.78 |
Beta | 0.541 |
Volatility | 94.55% |
Current Volume | 28.6k |
Average Volume 20d | 20.4k |
Stop Loss | 17 (-3.7%) |
As of July 09, 2025, the stock is trading at EUR 17.65 with a total of 28,557 shares traded.
Over the past week, the price has changed by +0.48%, over one month by -2.40%, over three months by +10.77% and over the past year by +24.89%.
Neither. Based on ValueRay´s Analyses, Lyxor MSCI China - Acc is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -14.07 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of L4K3 is around 16.60 EUR . This means that L4K3 is currently overvalued and has a potential downside of -5.95%.
Lyxor MSCI China - Acc has no consensus analysts rating.
According to our own proprietary Forecast Model, L4K3 Lyxor MSCI China - Acc will be worth about 18.7 in July 2026. The stock is currently trading at 17.65. This means that the stock has a potential upside of +6.06%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 18.7 | 6.1% |